MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
11.46
+0.52
+4.75%
After Hours: 11.46 0 0.00% 16:20 02/06 EST
OPEN
11.19
PREV CLOSE
10.94
HIGH
11.81
LOW
11.01
VOLUME
1.60M
TURNOVER
--
52 WEEK HIGH
14.39
52 WEEK LOW
3.771
MARKET CAP
1.47B
P/E (TTM)
-30.8728
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI)
TipRanks · 21h ago
Weekly Report: what happened at TRVI last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at TRVI last week (0119-0123)?
Weekly Report · 01/26 09:07
Trevi announces publication of data from Phase 2b IPF chronic cough trial
TipRanks · 01/22 17:35
Trevi Therapeutics' Phase 2b CORAL Trial Results Published In JAMA Shows Nalbuphine ER Significantly Reduces Chronic Cough, With Over 60% Of Patients Achieving 50% Cough Reduction
Benzinga · 01/22 17:33
Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER in IPF Chronic Cough Trial
Reuters · 01/22 17:30
TREVI THERAPEUTICS ANNOUNCES PUBLICATION OF DATA FROM THE PHASE 2B IPF CHRONIC COUGH TRIAL OF NALBUPHINE ER IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA)
Reuters · 01/22 17:30
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)
TipRanks · 01/21 16:40
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.